Compare OFG & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OFG | RAPP |
|---|---|---|
| Founded | 1964 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2012 | 2024 |
| Metric | OFG | RAPP |
|---|---|---|
| Price | $46.77 | $35.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $45.17 | ★ $48.50 |
| AVG Volume (30 Days) | 214.8K | ★ 241.6K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | 8.27 | ★ 24.34 |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | $36.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.71 | $10.57 |
| 52 Week High | $46.85 | $42.27 |
| Indicator | OFG | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 45.86 |
| Support Level | $44.15 | $33.55 |
| Resistance Level | N/A | $41.18 |
| Average True Range (ATR) | 0.87 | 1.91 |
| MACD | 0.08 | -0.36 |
| Stochastic Oscillator | 75.88 | 22.71 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.